Warning letter
Stewart-Jackson Pharmacal Inc.: warning letter of Aug 17, 2001
FDA warning letter UCM178651 · New Orleans District Office
Key facts
| Reference number | UCM178651 |
|---|---|
| Company | Stewart-Jackson Pharmacal Inc. |
| Subject | Current Good Manufacturing Practices for Finished Pharmaceuticals/Adulterated |
| Issue date | Aug 17, 2001 |
| Posted date | Aug 17, 2001 |
| Issuing office | New Orleans District Office |
| Product type | Drugs |
| Country | 3 |
| Inspection city | Memphis |
| Inspection ZIP | 38118-7324 |
| Inspection start date | Jul 18, 2001 |
| Letter on fda.gov | web.archive.org |
At a glance
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: